Diagnostic Role of Aldoketoreductase family 1B10 (AKR1B10) in Hepatocellular Carcinoma and Benign Hepatic Lesions

Thesis

Submitted for Partial Fulfillment of Doctorate Degree in Pathology

By

Laila Magid Salah El-din Farid

Assistant Lecturer of Pathology, Faculty of Medicine, Ain Shams University

Supervised by

Prof. Sanaa Abd El-Maged Sammour

Professor of Pathology
Faculty of Medicine - Ain Shams University

Prof. Nedal Ahmed Hegazy

Professor of Pathology
Faculty of Medicine - Ain Shams University

Prof. Mohamed Helmy Abdel-Rahman

Professor of Pathology and Genetics College of Medicine - Ohio State University- USA

Prof. Eman Abdel-Salam Ibrahim

Professor of Pathology Faculty of Medicine - Ain Shams University

Ass. Prof. Hoda Hassan Abou-Gabal

Associate Professor of Pathology, Faculty of Medicine, Faculty of Medicine - Ain Shams University



سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost, I feel always indebted to AUAH, the Most Kind and Most Merciful.

It is with immense gratitude that I acknowledge the sincere tremendous support, Meticulous valuable input & kindness of my dear **Prof. Sanaa Abd El-Maged Sammour** Professor of Pathology, Faculty of Medicine, Ain Shams University, it was a great honor to work under her supervision, guidance and knowledge.

I am profoundly grateful to my dear **Prof. Medal**Ahmed Tbegazy, Professor of Pathology, Faculty of Medicine, Ain Shams University, the eminent hepatopathologist for her guidance, encouragement, cooperation and tremendous support.

Words stands short to express my gratitude to my dear mentor **Prof. Mohamed Helmy Abdel-Rahman** Pathology and Genetics, College of Medicine - Ohio State University- USA for giving me the opportunity of this learning experience, for believing in me, encouragement, guidance & patience through every step that changed my learning scope and concept. Thank you

My warmest thanks are expressed to, **Prof. Eman**Abdel-Salam Ibrahim Professor of Pathology, Faculty of Medicine, Ain Shams University, for her outstanding unlimited help, support and valuable comments.

I am also delighted to express my deepest gratitude and thanks to Ass. Prof. 7boda 7bassan Abou-Gabal, Assistant Professor of Pathology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

Acknowledgment

Cultural affairs and mission sector Ministry of Higher Education and Scientific Research for funding my joint supervision mission at Ohio state university – USA, (scholarship award from the ministry of higher education and state for scientific research and cultural affairs).

Team member of the laboratory of Professor Dr. Mohamed Abdul Rahman at the Ohio state university especially James B. Massengill, for his endless support, through every step of my technical work, Getachew Boru and Timothy Grossel.

Sustainable sciences institute, San Francisco, CA, USA for partially funding my project.

Pathology Department, National Liver institute, Faculty of Medicine, Menofia University, headed by distinguishable Prof. Nermeen Ihsan and her supportive team.

Words can never express my deepest gratitude for my beloved mum. I owe you my whole life and without you I would have never made it. I would like to dedicate this work to my Dear beloved supportive brother, my lovely angle Lara (thank you for your endless support), sweetest Haya and my dear beloved grandma. Thank you without your kind help and support this work could not have come to completion.

List of Contents

| Title | Page No. |
|--|----------|
| | |
| List of Tables | i |
| List of Figures | iv |
| List of Abbreviations | xi |
| Introduction | 1 |
| Aim of the Work | 4 |
| Review of Literature | |
| Epidemiology of HCC | 5 |
| Genomic Landscape and Driver Pathways in Liv | ver |
| Carcinogenesis | 20 |
| Pathology of Hepatocellular Carcinoma | 40 |
| ■ Immnunohistochemical Stains | 72 |
| AldoketoReducatse1 B10 (AKR1B10) | 78 |
| Management of HCC | 85 |
| Cell Lines | 91 |
| Materials and Methods | 94 |
| Results | 116 |
| Illustrative Images | 159 |
| Discussion | 181 |
| Summary | 209 |
| Conclusion | 212 |
| Recommendations | 214 |
| References | 216 |
| Archie Summary | |

List of Tables

| Table No. | Title Page | No. |
|--------------------|---|-----|
| Table (1): | Subtypes of Hepatocellular adenoma according the mutant gene, immunohistochemical findings reflecting the mutations, gender difference, | |
| Table (2): | histological characteristics | |
| Table (3): | Histopathological morphology based differentiation | |
| Table (4): | Tested markers used and | |
| Table (5): | immunoreactivity scoring Cell lines data and maintenance | |
| Table (6): | DNA extraction kit | |
| Table (7): | Primers Design for Cell Lines Tested | |
| , , | Genetic Alteration p53 Specific exon | 111 |
| Table (8): | Diagnoses of the studied cases | |
| Table (9): | Tumor Focality among studied cases | |
| Table (10): | Histopathologic type variant and architecture pattern of included HCC | |
| Table (11): | WHO based grading of included HCC | 120 |
| | cases | 122 |
| Table (12): | Other evaluated Microscopic parameters | 400 |
| T 11 (10) | in HCC cases (group A) | 123 |
| Table (13): | AKR1B10 expression in included all the groups (nesheel el names and replace | 194 |
| Table (14): | with groups) | 124 |
| | in relation to the studied parameters: | 126 |
| Table (15): | HSP70 IHC expression in the studied cases | 127 |

List of Tables

| Table No. | Title | Page | No. |
|--------------------|---|---------|------|
| Table (16): | HSP70 immunostaining expressio HCC cases in relation to the st | | |
| | parameters | | 129 |
| Table (17): | GPC3 IHC expression in the st | udied | |
| | cases | | 130 |
| Table (18): | GS IHC expression in the studied cas | | 131 |
| Table (19): | AKR1B10, HSP70, GPC3 and | | |
| | immunohistochemistry expression is | | |
| | studied groups | | 132 |
| Table (20): | Significance of diagnostic role of st | | |
| (0.1) | markers in group (A) versus Group (1 | | 133 |
| Table (21): | Significant diagnostic role of st | | |
| | markers in Group (A) versus Group | | 101 |
| T 11 (99) | (D) | | 134 |
| Table (22): | Significance of the diagnostic ro | | |
| | studied AKR1B10 in group (A) Vs (| _ | 135 |
| Table (23): | (E) Validation of diagnostic role of st | | 155 |
| Table (25): | markers in group (A) versus group (I | | |
| | (Specificity, Sensitivity, Positive | | |
| | Negative Predictive Values, Accuracy | | |
| | positive and negative likelihood ratio | - | 137 |
| Table (24): | Validation of diagnostic role of st | | 20 1 |
| _ = = , = | markers in Group A vs Group C | | |
| | (Specificity, Sensitivity, Positive | | |
| | Negative Predictive Values, Accurac | | |
| | positive and negative likelihood ratio |) | 139 |
| Table (25): | Validation of the combined to | usage | |
| | AK1B10 with HSP70 highest speci | ificity | |
| | in the differentiation between Gro | - | |
| | and Group B | | 141 |

List of Tables

| Table No. | Title | Page | No. |
|--------------------|---|------------------|-----|
| Table (26): | Combined IHC Panel usage of the tested antibodies in the diagnosis of arising in cirrhotic or non-circ background in differentiation of | HCC rhotic | |
| | corresponding Non-Tumorous tissue | | 142 |
| Table (27): | Combined IHC Panel usage of the tested antibodies in the diagnos | sis of | |
| Table (28): | (group A)Vs (group C &D) The gain of only two markers pa combination (both markers were pos | rallel | 143 |
| Table (29): | in the diagnosis of group A vs group The gain of only two markers serial | B (only | 144 |
| Table (30): | one marker being positive) combinat the diagnosis of group A vs group B The gain of only two markers (both | | 145 |
| 1451c (50). | positive) combination in the diagno (group A)Vs (group C & D) | sis of | 146 |
| Table (31): | The gain of only one marker powhen combining only two markers in diagnosis of HCC arising in cirrho non-cirrhotic background in | in the tic or | |
| Table (32): | differentiation with HCA &FNH Gro AKR1B10 mRNA in comparison AKR1B10 immunohistoche | n to | 147 |
| Table (33): | expression in tumor versus non tumor Comparative analysis of AKR HSP70, GPC3 and GS expression in and IHC with data available on CO | 1B10, n WB | 155 |
| | and mRNA-AKR1B10 results | | 157 |

List of Figures

| Fig. No. | Title Page | No. |
|---------------------|---|-----|
| | | |
| Figure (1): | Global distribution of HCC | |
| Figure (2): | Hepatotropic virus role in hepatocarcinogenises | 12 |
| Figure (3): | HCV RNA and proteins perturb hepatocellular | |
| | homeostasis by driving major cancer hallmarks | 15 |
| Figure (4): | Genes and growth factors involved in activation of | |
| | cancer or normal hepatic stem cells | |
| Figure (5): | HCC molecular sub classifications | |
| Figure (6): | Histologic variants of hepatocellular carcinoma | 50 |
| Figure (7): | Barcelona Clinic Liver Cancer staging system | |
| | with predictive treatment choices according to the | _ |
| T! (0) | stage | |
| Figure (8): | Histological and immunostaining findings of HCA | |
| E: (0) | subtypes of HE staining of H-HCA | 59 |
| Figure (9): | (A) Hyperplasia fibrous segment the entire lesion | |
| | in nodular appearance; (B) the center of the | |
| | lesions showing scars formed by hyperplasia | |
| | fibrous and vascular malformation; Focal nodular hyperplasia. (C) This wedge resection was | |
| | sectioned after fixation, showing the umbilicated | |
| | central scar, radiating fibrous septa and pale | |
| | parenchymal nodules | 63 |
| Figure (10): | Liver biopsy tissue showed hepatocellular | 00 |
| rigure (10). | hyperplasia nodules Liver cell dysplasia | 65 |
| Figure (11): | LGDN portal structure was basically integral, | |
| 118410 (11) | HGDN trabecula was broadened in the central | |
| | region of the lesion; atypical hyperplasia was | |
| | obvious in the peripheral region. HGDN | 67 |
| Figure (12): | Aldose reductase with Chromosomal localization | |
| 3 , , | on 7q33 | 79 |
| Figure (13): | COSMIC based tested alteration in AKR1B10 | |
| Figure (14): | Mechanism of action of AKR1B10 | 84 |
| Figure (15): | Multidisciplinary integrated team in the | |
| . | management of HCC | 86 |
| Figure (16): | Targeting Altered Pathway in HCC with Current | |
| _ | Potential ttt in white, Future Potential ttt in | |
| | Purple, Activated Oncogene in Pink and | |
| | Inactivated Tumor Suppressor Gene in blue | 89 |
| Figure (17): | Cases studied and techniques carried out | 93 |

| Fig. No. | Title Page | e No. |
|---------------------|---|-------|
| Figure (18): | Cell Lines validation for sequence result and | |
| | alignment with the reference sequence provided in | |
| | ensembl | |
| Figure (19): | Gender distribution among HCC and NT cases | |
| Figure (20): | Gender distribution among groups (C), (D) and (E) | |
| Figure (21): | Viral Status & other Eitologies | |
| Figure (22): | Histopathologic Type | |
| Figure (23): | Tumor (Architecture) Pattern of Classical Variant. | |
| Figure (24): | AKR1B10 expression in included all the groups | |
| E' . (05) | (nesheel el names and replace with groups) | |
| Figure (25): | Hsp70 expression in the studied cases | |
| Figure (26): | GPC3 expression in all the studied groups. | |
| Figure (27): | GS expression in studied groups. | |
| Figure (28): | Significance of Studied Markers Expression in | |
| Figure (20). | Group A and Group B | |
| Figure (29): | Significance of Studied Markers Expression in | |
| Figure (30): | HCC (T) group A and Group (C) & (D)AKR1B10 Expression in group (A) HCC vs group | |
| rigure (50): | (E) | |
| Figure (31): | Specificity & Sensitivity in HCC (T) group and | |
| rigure (51). | Non-Tumor(NT) | 138 |
| Figure (32): | The Accuracy of the Studied Antibodies in the | |
| 1 1gui C (02). | HCC (T) and Non-Tumor (NT) Groups. | |
| Figure (33): | Specificity & Sensitivity in the diffrantation | |
| 1 1gui C (00). | Group A and Group C & D for the Studied | |
| | | 140 |
| Figure (34): | The Accuracy of the Studied Antibodies in group A | |
| 8 | and Group C &D. | |
| Figure (35): | Expression of tested antibodies on the studied cell | |
| 3 | | 148 |
| Figure (36): | AKR1B10, HSP70, GS and GPC3 expression on | |
| J | studied cell lines | 148 |
| Figure (37): | AKR1B10 expression on the studied Cell Lines | 149 |
| Figure (38): | AKR1B10 Expression in Comparison to the | |
| _ | Loading Control Antibody on Studied HCC Cell | |
| | Lines) | 149 |
| Figure (39): | HSP70 expression on the studied Cell Lines | 150 |
| Figure (40): | HSP70 Antibody expression in comaprasion to the | |
| | Laoding antibosy B-Actin | 150 |
| Figure (41): | Glypican (3) GPC3 expression on the studied Cell | |
| | Lines | 151 |

| Fig. No. | Title Page No |) |
|---------------------|--|------|
| Figure (42): | GPC3 Antibody Expression in comparison to | |
| | loading antibody B-Actin | 151 |
| Figure (43): | Glutamine Synthetase (GS) expression on the | |
| | studied Cell Lines | 152 |
| Figure (44): | GS Expression in comparison to loading antibody B Actin | 152 |
| Figure (46): | AKR1B10 mRNA level in HCC and coressponding | |
| 3 , , | NT | 155 |
| Figure (47): | AKR1B10 mRNA Level in Studied HCC Cell | |
| _ | Lines | 156 |
| Figure (48): | Tissue microarray slides and blocks (H&E) | |
| | allowing a massive acceleration of simultaneous | |
| | studies of thousands of retrieved cases with | |
| | technical, cost and labor efficiency | 159 |
| Figure (49): | Group A: A) HCC Grade II (Acinar and | |
| | trabecular pattern) (H&E 40x). B) HCC showing | |
| | positivity +3 for AKR1B10 >50% of the cells (AKR1B10 40x). Group B: C) Corresponding non | |
| | tumour (NT) cirrhotic hepatic tissue showing | |
| | positivity >10% (moderate to strong nuclear, | |
| | cytoplasmic and or membranous) staining for GPC3 | |
| | (GPC3 40x). D): NT cirrhotic hepatic tissue showing | |
| | complete negativity for HSP70 (HSP70 40x). | 160 |
| Figure (50): | Group A: HCC Grade II (acinar and trabecular | |
| | pattern) (H&E 100). | 161 |
| Figure (51): | Group A: HCC Grade II (trabecular pattern) (H&E | |
| | 200). | 161 |
| Figure (52): | Group A: HCC Grade III (acinar and trabecular | 1.00 |
| E' . (50) | pattern) (H&E 200). | |
| Figure (53): | Group A: HCC Grade IV (Solid pattern) (H&E 400) | 162 |
| Figure (54): | Intestinal mucosa showing positivity +3 for AKR1B10 >50% of the cells as external positive | |
| | control (AKR1B10 100x) | 163 |
| Figure (55): | Group A: HCC: Grade II (acinar and trabecular | 100 |
| Bui c (00) | pattern) showing positivity +3 for AKR1B10 >50% of | |
| | the cells and nearby NT showing complete | |
| | negativity for AKR1B10 (AKR1B10 200x). | 163 |

| Fig. No. | Title Pag | e No. |
|--------------|--|-----------------------|
| Figure (56): | Group A: A) HCC Grade II (acinar and trabecular pattern) showing positivity +3 for AKR1B10 >50% of the cells (AKR1B10 400x), higher magnification of the previous image. B) HCC Grade III (acinar and trabecular pattern) showing positivity +2 for AKR1B10 10-50% of the cells (AKR1B10 200x). CHCC Grade III (Solid and trabecular pattern showing positivity +2 for AKR1B10 5 – 10% of the cells (AKR1B10 400x). D) HCC Grade IV (solid and trabecular pattern) showing positivity +1 for AKR1B10 5 – 10% of the cells (AKR1B10 400x) | f f l)) |
| Figure (57): | Group A: A) Case 1): HCC Grade I (H&E 200x). B) Case 2): HCC Grade II (acinar pattern) (H&E200x) C) Case 3): Hepatocellular Carcinoma Grade III (acinar and trabecular pattern) (H&E200x) Group A. D) Case 4): Hepatocellular Carcinoma Grade III (trabecular and solid pattern) (H&E 400x) Group A. |) [) [|
| Figure (58): | Group A: Case 1) A): AKR1B10 showed positivity + 3 (> 50% of the cells) in HCC Grade I (AKR1B10 100x). B) HSP70 showed positivity >10% nuclear staining in HCC Grade I (HSP70 100x). C) GS showed positivity > 50% of the cells in HCC Grade I (GS 100x). D) GPC3 showed positivity > 10% nuclear cytoplasmic and or membranous staining in HCC Grade I (GPC3 100x) | 7) : : : |
| Figure (59): | Group A: Case 2: A) AKR1B10 showed positivity +8 > 50% of the cells in HCC Grade II (AKR1B10 200x) B) HSP70 showed positivity >10% nuclear staining HCC Grade II (HSP70 200x). C) GS showed complete negativity in HCC Grade II (GS 200x). D) GPC3 showed positivity >10% nuclear, cytoplasmic and or membranous staining in HCC Grade II (acinar pattern) showing (GPC3 200x). | 8 1 9 |

| Fig. No. | Title | Page No. |
|---------------------|--|---|
| Figure (60): | Group A: Case 3: A) AKR1B10 showed pos > 50% of the cells in HCC Grade II (AKR1BB) HSP70 showed positivity >10% nuclear HCC Grade II (HSP70 200x). C) GS positivity > 50% of the cells (GS 200x). It positivity >10% nuclear, cytoplasmic | 310 200x). r staining s showed D) GPC3 |
| Figure (61): | membranous staining in HCC Grade II (GP Group A: Case 4: A) AKR1B10 showed +2, 10-50% of the cells in HCC Grade III (tand solid pattern) (AKR1B10 400x). Be showed positivity >10% nuclear staining Grade III (trabecular and solid pattern) 400x). C) GS showed positivity > 50% of HCC Grade III (trabecular and solid pattern) 400x). D) GPC3 positivity showed | positivity rabecular) HSP70 ng HCC) (HSP70 the cells tern) (GS complete |
| Figure (62): | negativity HCC Grade III (trabecular a pattern) (GPC3 400x) | negativity o showed 100x). C) f cirrhotic o nuclear, ining in |
| Figure (63): | Group B: Corresponding cirrhotic NT complete negativity for AKR1B10 (AK1B10 | showing |
| Figure (64): | Group B: showing positivity for GPC3 >10% nuclear, cytoplasmic and or mer staining in cirrhotic NT (GPC3x100) at negative for the rest of the markers in | positivity nbranous nd being |
| Figure (65): | case | showing sparse ıl thick- |
| Figure (66): | Group C: Higher magnification of the figure (H&E 200x). | previous |

| Fig. No. | Title Page No. |
|---------------------|--|
| Figure (67): | Group C: A) FNH showing complete negativity for AKR1B10 expression (AKR1B10 100x). B) Higher magnification of the previous figure (200x). C) FNH showing map like positivity for GS expression (40x). D) FNH showing diffuse |
| TI (00) | positivity for GPC3 expression (100x) |
| Figure (68): | Group D: Hepatocelular adenoma showing bland neoplasm with thick capsule (H&E 40x) |
| Figure (69): | Group D: Hepatocelular adenoma higher |
| 119410 (00) | magnification of the previous image (H&E 200x) |
| Figure (70): | Group D: A) HCA showing complete negativity for AKR1B10 expression (200x). B) HCA showing complete negativity for HSP70 expression (40x). C) HCA showing negativity for GS expression (100x) group D with pericentral hepatic plate normal immunoreactivity for GS. D) HCA showing negativity for GPC3 expression (100x) |
| Figure (71): | Group E: Cirrhosis without HCC Non-Tumor (NT) |
| J | (H&E x 100) |
| Figure (72): | Group E: Cirrhosis without HCC showing complete negativity for AKR1B10 with lymphoid aggregates in portal tracts which more associated with HCV related hepatitis (AKR1B10 x100) |
| Figure (73): | Cell line group: A) SNU_423 showing epithelial cells with adherent cell culture properties Brightfield (inverted microscope images) (200x). B) SNU_475 showing epithelial cells with adherent monolayer of diffused spreading cells in cell culture properties Bright-field (inverted microscope images) (100x). C) SNU_449 showing diffuse spreading with adherent cell culture properties Bright-field (inverted microscope images) (100x). D) SKHEP1 showing epithelial cells with adherent cell culture properties with very low confluence Bright-field (inverted microscope images) (100x) |

| Fig. No. | Title Page | No. |
|--------------|---|-----|
| Figure (74): | Cell line group: Huh7 showing epithelial-like tumorgenic cells growing in 2D monolayers (high cellular confluence 100%) Bright-field (inverted microscope images) (100x). B) Huh7 showing epithelial-like tumorgenic cells growing in 2D monolayers (less cellular confluence) Bright-field (inverted microscope images) (100x). C) C3A epithelial-like cells with adherent cell culture properties Bright-field (inverted microscope images) (100x). D) PLC/PRF/5 showing epithelial cells with adherent cell culture properties Bright-field (inverted microscope images) (100x). | 170 |
| Figure (75): | field (inverted microscope images) (200x) | |
| Figure (76): | Cell line group: A) PLC/PRF/5 showing hepatoma (H&E x100). B) PLC/PRF/5 showing hepatoma with positivity for HSP70 (HSP70 x100). C) SNU_475 showing hepatocellular carcinoma grade II-IV (H&E x200). D) SNU_475 showing hepatocellular carcinoma with negativity for AKR1B10 grade II-IV (AKR1B10 x200) | 180 |